NanoViricides, Inc. (NNVC)

ASE – Real vaqt narxi. Valyuta: USD

1.50

+0.01 (0.67%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2026, at The Plaza Hotel in New York City.

04.05.2026

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NanoViricides (NYSE-A:NNVC) said on Monday its broad-spectrum antiviral drug NV-387 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration, a regulatory milestone the company said could help accelerate the drug's path to approval as a measles treatment. The designation, granted by the FDA's Office of Orphan Products Development, makes NanoViricides eligible for tax credits on qualified clinical trials, exemption from certain user fees, and up to seven years of market exclusivity following approval.

04.05.2026

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD). The orphan drug designation will qualify NanoViricides for incentives including: Tax credits for qualified clinical trials; Exemption from certain user fees; Potential seven years of market exclusivity after approval; according to the US FDA[1].

21.04.2026

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

NanoViricides (NYSE-A:NNVC) said on Tuesday its antiviral drug candidate NV-387 could help address rising measles cases globally, citing recent outbreaks and unmet treatment needs. The company pointed to data from Bangladesh showing 18,219 suspected measles cases over the last month, with transmission reported in most districts.

21.04.2026

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments that its drug candidate NV-387 is the weapon necessary for combatting growing cases of deadly measles worldwide. Bangladesh recently reported 18,219 suspected measles cases, including 2,897 confirmed cases, and 164 suspected case deaths, with transmission in 58 of 64 districts, in the single month of March 15 to April 14, 2026[1].

11.04.2026

NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

NanoViricides (NYSE-A:NNVC) CEO Dr. Anil Diwan talked with Proactive about the company's recent FDA application for rare pediatric disease designation for its antiviral candidate NV-387, highlighting both the scientific and commercial implications of the move.

07.04.2026

NanoViricides seeks rare pediatric disease status for measles drug NV-387

NanoViricides (NYSE-A:NNVC) said on Tuesday it has filed an application with the US Food and Drug Administration for Rare Pediatric Disease Drug designation for its antiviral candidate NV-387 as a treatment for measles. The clinical-stage company said the application, submitted to the FDA's Office of Orphan Products Development, is expected to be reviewed alongside a separate orphan drug designation request filed in February.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

04.05.2026

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

21.04.2026

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

07.04.2026

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.

NanoViricides, Inc. (NNVC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NanoViricides, Inc. (NNVC)

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

NanoViricides seeks rare pediatric disease status for measles drug NV-387

Videolar

No Data

Press-relizlar

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

NanoViricides seeks rare pediatric disease status for measles drug NV-387

Videolar

No Data

Press-relizlar

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Search stocks

NanoViricides, Inc. (NNVC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NanoViricides, Inc. (NNVC)

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

NanoViricides seeks rare pediatric disease status for measles drug NV-387

Videolar

No Data

Press-relizlar

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

NanoViricides seeks rare pediatric disease status for measles drug NV-387

Videolar

No Data

Press-relizlar

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides